摘要
采用原子吸收分光光度法等对肝硬化和肝癌患者体内铜含量（Ｃｕ）和血清铜蓝蛋白（Ｃｐ）进行了测定。结果表明：①肝硬化患者血清Ｃｐ和尿Ｃｕ高于正常人（Ｐ＜０．０５和０．０１）。②肝癌患者血清Ｃｕ与Ｃｐ呈一致性升高；尿Ｃｕ明显升高且与血请Ｃｕ呈正相关（ｒ＝０．５６７，Ｐ＜０．０１）。③硬化肝Ｃｕ与癌周组织（有肝硬化改变）相近并高于正常肝和肝癌组织。④肝硬化和肝癌组头发Ｃｕ均明显低于对照组（Ｐ＜０．０１）。⑤大肝癌患者血清Ｃｕ明显高于小肝癌患者（Ｐ＜０．０５）。⑥治疗后肝癌缩小与血清Ｃｕ降低相一致。⑦血清Ｃｕ和Ｃｐ可作为诊断肝癌、特别是甲胎蛋白（ＡＦＰ）阴性肝癌的辅助指标，前者亦可作为判断疗效的参考指标。
opper contents(Cu) in bodies and serum ceruloplasmin(Cp) were assayed in patients with livercirrhosis (LC) and hepatocarcinoma(HCC)with atomic absorption and other methods.The resultswere shown as folIows: 1.The mean levels ofserum Cp and urine Cu in LC were higher than those ofnormal(P< 0.05 and 0.01).2. Serum Cu and Cp levels were consistently high in HCC.Urine Cu levelwas also elevated and had positive correlation with that of serum Cu(r =0.567, P< 0.01).3. Cirrhoticliver Cu content was almost the same as that of pericarcinomatous liver Cu, being higher than that ofnormal and carcinomatous liver.4.Hair Cu level in both LC and HCC was apparently lower than thatof normal subjects.5.Serum Cu level in patients with tumor more than 5 cm in size was higher than thatin patients with tumor less than 5 cm (P< 0.05).6. Serum Cu level decreased along with the reduction oftumor size after treatment.7. Serum Cu and Cp levels may be used as markers for detection of HCC,especially for AFP-negative HCC. Serum Cu estimation is valuable in assessment of the therapeutic ef-fect and prognosis in patients with HCC.
出处
《中华内科杂志》
CAS
CSCD
北大核心
1994年第2期113-116,共4页
Chinese Journal of Internal Medicine
关键词
肝硬变
肝肿瘤
铜
Liver cirrhosis Liver neoplasms Copper
